bamlanivimab

Pronunciation: BAM la NIV i mab

What is the most important information I should know about bamlanivimab?

The FDA has authorized emergency use of bamlanivimab together with another medicine called etesevimab to treat people with COVID-19 who are not in a hospital or using supplemental oxygen.

Bamlanivimab has not been approved to treat coronavirus or COVID-19.

What is bamlanivimab?

Bamlanivimab is an experimental medicine being studied for use in treating conditions caused by coronavirus. It is not yet known if bamlanivimab is safe and effective.

The US Food and Drug Administration (FDA) has authorized emergency use of bamlanivimab given together with another medicine called etesevimab to treat mild to moderate COVID-19. These medicines are for use only in adults and children at least 12 years old and weighing at least 88 pounds (40 kilograms). Bamlanivimab with etesevimab is for use only in people who test positive for COVID-19 and have a high risk of symptoms becoming severe enough to need treatment in a hospital.

The risk of COVID-19 symptoms becoming severe may be higher in people with:

  • a high body mass index (BMI) of 25 or higher;
  • chronic kidney disease;
  • diabetes;
  • a weak immune system (caused by disease or by using certain medicine);
  • a heart problem;
  • sickle cell disease;
  • a neurodevelopmental disorder such as cerebral palsy;
  • asthma or other chronic breathing disorder needing daily medication to control; or
  • a tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19).

There also may be a higher risk of severe COVID-19 symptoms in adults who are:

  • 65 years of age or older; or
  • 55 years of age or older AND have heart disease, high blood pressure, or lung disease such as chronic obstructive pulmonary disease (COPD).

There also may be a higher risk of severe COVID-19 symptoms in children (12 and older weighing at least 88 lbs or 40 kg) who have a BMI at or above the 85th percentile for age and gender.

Bamlanivimab has not been approved to treat coronavirus or COVID-19. However, this medicine given together with etesevimab may help prevent the need for emergency medical care or admission to a hospital because of COVID-19. Bamlanivimab with etesevimab is not authorized for use in people who are already in the hospital or receiving supplemental oxygen for COVID-19.

Bamlanivimab may also be used for purposes not listed in this medication guide.

What should I discuss with my healthcare provider before receiving bamlanivimab?

Tell your doctor if you have ever had:

  • any serious or chronic illness;
  • any allergies; or
  • if you are pregnant or breastfeeding.

COVID-19 is more likely to cause serious illness or death in a pregnant woman. Not all risks are known yet, but being treated with bamlanivimab and etesevimab is likely to be less harmful than being infected with COVID-19 during pregnancy.

How is bamlanivimab given?

Bamlanivimab and etesevimab are injected into a vein by healthcare provider.

These medicines are injected slowly over 21 to 70 minutes. You will be watched for a short time to make sure you do not have an allergic reaction.

Bamlanivimab with etesevimab is usually given as only one dose as soon as possible after you test positive for COVID-19, or within 10 days after the start of symptoms.

Being treated with bamlanivimab and etesevimab will not make you less contagious to other people. Keep using infection control methods such as self-isolation, social distancing, hand-washing, using protective face covering, disinfecting surfaces you touch a lot, and not sharing personal items with others.

These medicines also may not keep you from becoming infected with coronavirus again. Being treated with bamlanivimab and etesevimab could also affect your body's immune response to a coronavirus vaccine. Bamlanivimab and etesevimab are still being studied and all of the risks are not yet known.

What happens if I miss a dose?

Bamlanivimab is given with etesevimab in a single dose and does not have a daily dosing schedule.

What happens if I overdose?

In a medical setting an overdose would be treated quickly.

What should I avoid after receiving bamlanivimab?

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

What are the possible side effects of bamlanivimab?

Get emergency medical help if you have signs of an allergic reaction: hives, itching; difficult breathing; swelling of your face, lips, tongue, or throat.

Some side effects may occur during the injection. Tell your caregiver right away if you have:

  • throat irritation, swelling in your face or throat;
  • fever, chills, sweating;
  • a rash or itching;
  • dizziness, a light-headed feeling (like you might pass out);
  • wheezing, shortness of breath;
  • nausea;
  • chest pain, fast or slow heartbeats, pounding in your neck or ears;
  • headache, change in your mental status; or
  • muscle pain.

Call your doctor if you have new or worsening symptoms after the infusion, such as fever, loss of taste or smell, confusion, tiredness, cough, trouble breathing, or chest pain.

Less serious side effects may also occur, or you may have none at all. Not all possible side effects are known.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect bamlanivimab?

Other drugs may affect bamlanivimab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.

Where can I get more information?

Your doctor or pharmacist can provide more information about bamlanivimab.

This information does not replace the advice of a doctor. Healthwise, Incorporated, disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. Learn how we develop our content.

Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.